Nexsen Limited
NXN.ASXHealth Care
The Company is a nanobiotechnology company, dedicated to the development of proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural and biosecurity applications.
Market Data
$0.253
+0.0%$50.0M
-100000.0x
$-99999.990
0.00%
+0.1%
Latest Earnings
Quarterly Report - Q3 FY26
28 April 2026
Nexsen Limited achieved significant de-risking milestones in Q3 FY26, with FDA confirmation of the 510(k) pathway for StrepSure® and successful completion of ISO 13485 Stage 1 audit, positioning the company for U.S. market entry targeting Q4 2026. The company secured A$1.7 million in non-dilutive government grants (HK$6M IGNITE grant + A$0.5M Australian grant) and launched a global rollout strategy targeting Hong Kong, Malaysia, India and emerging markets, with total non-dilutive funding now exceeding A$13 million. Nexsen ended the quarter with A$5.73 million in cash reserves and approximately 5 quarters of funding runway based on current burn rate. Key points: FDA confirms 510(k) regulatory pathway for StrepSure® during Q-Submission meeting, de-risking U.S. market entry with clear and lower-risk pathway to approval; Secured A$1.7 million in non-dilutive government grants in single quarter: HK$6 million (A$1.2M) IGNITE Grant for Hong Kong manufacturing hub and A$0.5 million Australian Commonwealth grant for neonatal GBS expansion; Successfully completed ISO 13485 Stage 1 audit with critical milestone passed; Stage 2 certification anticipated in early Q3 2026 with MDSAP alignment to follow
Recent Announcements
Becoming a substantial holder
Ajava Holdings Pty Ltd became a substantial holder of Nexen Ltd on 8 May 2026, acquiring 12,600,000 FPO shares representing 5.97% voting power. The acquisition was made for cash consideration as detailed in the appendix.
Quarterly Report - Q3 FY26
Nexsen Limited achieved significant de-risking milestones in Q3 FY26, with FDA confirmation of the 510(k) pathway for StrepSure® and successful completion of ISO 13485 Stage 1 audit, positioning the company for U.S. market entry targeting Q4 2026. The company secured A$1.7 million in non-dilutive government grants (HK$6M IGNITE grant + A$0.5M Australian grant) and launched a global rollout strategy targeting Hong Kong, Malaysia, India and emerging markets, with total non-dilutive funding now exceeding A$13 million. Nexsen ended the quarter with A$5.73 million in cash reserves and approximately 5 quarters of funding runway based on current burn rate. Key points: FDA confirms 510(k) regulatory pathway for StrepSure® during Q-Submission meeting, de-risking U.S. market entry with clear and lower-risk pathway to approval; Secured A$1.7 million in non-dilutive government grants in single quarter: HK$6 million (A$1.2M) IGNITE Grant for Hong Kong manufacturing hub and A$0.5 million Australian Commonwealth grant for neonatal GBS expansion; Successfully completed ISO 13485 Stage 1 audit with critical milestone passed; Stage 2 certification anticipated in early Q3 2026 with MDSAP alignment to follow
Get real-time alerts for NXN
Receive AI-powered earnings summaries and instant notifications when Nexsen Limited releases results.
Register Free